4.60
2.34%
-0.11
Vorhandelsmarkt:
4.46
-0.14
-3.04%
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc ... - PR Newswire
PR Newswire
Abeona Therapeutics (NASDAQ:ABEO) Price Target Cut to $21.00 by Analysts at Cantor Fitzgerald - MarketBeat
MarketBeat
Abeona Therapeutics' (NASDAQ:ABEO) Shareholders Are Down 85% On Their Shares - Yahoo Sport Australia
Yahoo Sport Australia
Is Abeona Therapeutics (ABEO) Outperforming Other Medical Stocks This Year? - Yahoo Movies UK
Yahoo Movies UK
Abeona Therapeutics bolsters finances as it seeks FDA approval for a key treatment - Crain's Cleveland Business
Crain's Cleveland Business
Abeona Therapeutics: Q1 Earnings Snapshot | Region | dailyindependent.com - The Independent
The Independent
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress - GlobeNewswire
GlobeNewswire
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
GlobeNewswire Inc.
Abeona Therapeutics Inc (NASDAQ:ABEO) Sees Significant Increase in Short Interest - MarketBeat
MarketBeat
Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Up 62.6% in April - Defense World
Defense World
Abeona Therapeutics to Present at Jefferies Gene Editing & Gene Therapy Summit - Yahoo News UK
Yahoo News UK
Abeona Therapeutics (NASDAQ:ABEO) Stock Passes Below Fifty Day Moving Average of $6.90 - MarketBeat
MarketBeat
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Canada Finance
Yahoo Canada Finance
Abeona Therapeutics (NASDAQ:ABEO) Share Price Passes Below 50 Day Moving Average of $6.90 - Defense World
Defense World
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Canada Finance
Yahoo Canada Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc ... - PR Newswire
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc ... - PR Newswire
PR Newswire
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Public equity report: Soleno, Abeona raise capital for late-stage rare disease programs - BioCentury
BioCentury
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics ... - Business Wire
Business Wire
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL (ABEO) - Seeking Alpha
Seeking Alpha
We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate - Simply Wall St
Simply Wall St
Abeona Therapeutics director acquires $24.7k in stock By Investing.com - Investing.com
Investing.com
Faith L. Charles Buys 7,550 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock - MarketBeat
MarketBeat
Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O'malley Purchases 8600 Shares - Defense World
Defense World
Abeona Therapeutics executive buys $27,864 in company stock By Investing.com - Investing.com Canada
Investing.com Canada
SHAREHOLDER ALERT: Abeona Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations ... - GlobeNewswire
GlobeNewswire
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Abeona Th - Benzinga
Benzinga
Abeona Therapeutics Provides Regulatory Update on Pz-cel
GlobeNewswire Inc.
FDA requests additional data from Abeona for RDEB therapy - Investing.com
Investing.com
(ABEO) Technical Pivots with Risk Controls - Stock Traders Daily
Stock Traders Daily
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Here's Why We're Not Too Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation - Yahoo Finance
Yahoo Finance
Abeona Therapeutics Full Year 2023 Earnings: EPS Misses Expectations - Simply Wall St
Simply Wall St
Abeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial Results - GuruFocus.com
GuruFocus.com
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
GlobeNewswire Inc.
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections - GlobeNewswire
GlobeNewswire
Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump - Yahoo Movies Canada
Yahoo Movies Canada
Several Insiders Invested In Abeona Therapeutics Flagging Positive News - Yahoo Finance
Yahoo Finance
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Hedge funds investors have a lot riding on Abeona Therapeutics Inc. (NASDAQ:ABEO) with 33% ownership - Simply Wall St
Simply Wall St
Steven Cohen's Firm Increases Stake in Abeona Therapeutics Inc - Yahoo Finance
Yahoo Finance
Thinking about buying stock in BioXcel Therapeutics, Hitek Global, Abeona Therapeutics, Mullen Automotive, or ... - Marketscreener.com
Marketscreener.com
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Benzinga
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying - Abeona Therapeutics (NASDAQ:ABEO) - Benzinga
Benzinga
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
GlobeNewswire Inc.
When Will Abeona Therapeutics Inc. (NASDAQ:ABEO) Become Profitable? - Simply Wall St
Simply Wall St
Abeona Therapeutics Inc. (NASDAQ:ABEO): When Will It Breakeven? - Yahoo Finance
Yahoo Finance
Abeona Therapeutics Announces $50 Million Credit Facility - GlobeNewswire
GlobeNewswire
Kapitalisierung:
|
Volumen (24h):